Try to use it on the same day each week for consistency
Obesity in people living with type 1 diabetes
Contraindications also exist for patients with known hypersensitivity reactions to other brand-name and generic formulations of semaglutide and tirzepatide
Advise patients to inform their healthcare provider of a known or suspected pregnancy
Recent studies have claimed clinical benefits in patients with heart and kidney failure, arthritis, and sleep apnea disorders, mediated in part through anti-inflammatory and metabolic pathways, with some benefits partly independent of the degree of weight loss achieved

STEP 1 showed 14.9% body weight reduction at 2.4 mg weekly SELECT trial : Cardiovascular outcomes study showing 20% MACE reduction in patients with obesity and established CVD without diabetes FLOW trial : Kidney outcomes data demonstrating renal protective effects Oral formulation : Rybelsus provides an oral dosing option at 7-14 mg daily Real-world data : Millions of prescriptions written, providing extensive post-marketing safety surveillance Survodutide Research# Survodutide's evidence base is growing but not yet mature: Phase 2 obesity trial : Demonstrated dose-dependent weight loss up to approximately 19% body weight reduction, exceeding typical GLP-1 monotherapy results Phase 2 MASH data : Histological improvement in liver biopsies, including reduction in hepatic steatosis and inflammation scores Phase 3 programs : Active Phase 3 trials for both obesity and MASH, with results anticipated to define the compound's clinical profile Mechanism validation : Clinical data support the dual mechanism concept, with evidence of both appetite reduction and increased energy expenditure Limitation : No regulatory approvals
